Non-alcoholic Fatty Liver Disease
Conditions
Interventions
Group I (SOP I): 30 patients will receive 3 capsules containing 1g of fish oil with 420 mg of EPA and 220 mg of DHA each once a day during the 12-month period.
Group II (SOP II): 30 patients will rece
Dietary supplement
D10.251.355
B01.650.940.800.575.100.100.525
Sponsors
Universidade Federal do Rio de Janeiro
Universidade Federal do Rio de Janeiro
Eligibility
Inclusion criteria
Inclusion criteria: Be 19 years of age or older; diagnosis of NAFLD by abdominal ultrasonography, and liver biopsy in the last 24 months preceding the intervention
Exclusion criteria
Exclusion criteria: Viral hepatitis; infectious fever or outbreaks; cancer with or without chemotherapy and radiotherapy; inflammatory diseases of the gastrointestinal tract; transplant, trauma, surgery or hospitalization in the last 30 days; use of steroids or non-steroidal anti-inflammatories or immunomodulatory agents or antibiotics; use of n-3 fatty acid supplement in the last 3 months prior to study; pregnancy and lactation; alcohol intake greater than 20g / day for women and 30g / day for men
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Regression of NAFLD by decreasing the expression of miRNAs related to this liver, quantified by real-time PCR at baseline and after 180 days of supplementation with fish oil rich in n-3 PUFA and Milk Thistle (Silybum marianum L.), from the observation of a variation of at least 5% in the pre- and post-intervention measurements. | — |
Secondary
| Measure | Time frame |
|---|---|
| Increased n-3 polyunsaturated fatty acids in the plasma evaluated by gas chromatography, from the observation of a variation of at least 5% in the pre and post intervention measurements. | — |
Countries
Brazil
Contacts
Public ContactKatia Cansanção de Oliveira
Instituto de Nutrição Josué de castro
Outcome results
None listed